⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AZN News
AstraZeneca PLC
Esophageal Cancer - 7MM Market Insights, Epidemiology, Competitive Landscape, and Forecast - 2036 | 6.0% CAGR Fueled by Immunotherapy and Precision Oncology
globenewswire.com
MRK
BMY
AZN
ABBV
AMGN
JAZZ
ZYME
BIIB
High-Stakes October has these Biotechs Entering Crucial Stretch
globenewswire.com
IOVA
NTHI
SMMT
AZN
Sonar Extends Agentic Code Governance and Verification to Self-Managed Infrastructure
prnewswire.com
NVDA
NOW
GS
AZN
F
Graphwise Upgrades its AI Context Platform to Help Enterprises Build Seamless Context Layers and Unlock Smarter Multilingual AI
prnewswire.com
ACN
SPGI
AZN
Providence Therapeutics Announces Formation of Oncology Clinical Advisory Board
prnewswire.com
AZN
BDTX
Canada RNA Therapeutics Market by Molecule Type, Therapeutic Area, Administration Route, End User, and Province, Forecast to 2035 | 13.4% CAGR to Unlock a USD 3.56 Billion Market
globenewswire.com
PFE
AZN
Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer
globenewswire.com
AZN
GILD
MRK
PFE
BMY
JNJ
TEVA
Global Aptamer-Drug Conjugates Market Outlook, 2026-2032 - AI-Enabled Discovery and Precision Delivery Drive Growth Toward USD 2.14 Billion at a 15.79% CAGR
globenewswire.com
ABBV
ADCT
AZN
BMY
GSK
MRK
PFE
ROG
TAK
ZYME
Global Cyclic Peptide Library Market Outlook and Forecast, 2026-2032 - AI-Enabled Discovery Fuels 16.32% CAGR Toward USD 9.86 Billion as PeptiDream, Bicycle Therapeutics, Pfizer and Roche Advance Competition
globenewswire.com
PFE
AMGN
AZN
EVTC
MRK
NVS
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
businesswire.com
AZN